DeepIntent has introduced Helix AI, an agentic AI solution designed to enable healthcare marketers to obtain insights from large datasets through natural-language queries. The launch expands the company’s data-driven marketing offerings for biopharma organizations and agencies seeking faster access to audience and campaign intelligence. DeepIntent’s demand-side platform is used by companies including Amgen, AstraZeneca, Gilead, Merck & Co. and Teva to plan, launch and monitor digital marketing campaigns.
The new offering builds on Helix, a product DeepIntent introduced in March that opened the data infrastructure supporting its own solutions to agencies such as Deerfield, Eversana, Klick Health and Trinity. Through Helix AI, marketers can interact with a database covering 4 million healthcare providers and 250 million patient lives. The technology is intended to streamline activities including audience sizing, prescriber overlap analysis and campaign performance measurement by reducing reliance on traditional database workflows.
Industry users say the technology can significantly reduce the time required for complex analysis. “Helix AI provides a strategic edge by putting advanced, purpose-built data capabilities directly into the hands of our strategists,” Liz Mansell, senior vice president, media strategy at Fingerpaint Marketing, said in a statement. “Analysis that once took days, and often wasn’t feasible at this depth, now takes minutes.” Agencies are also able to tailor the platform with their own first-party analytics, media assets and data sources. Supporters of the underlying Helix platform have highlighted efficiency gains, with Paul Cross, vice president, data strategy and reporting at Deerfield, stating in a DeepIntent video that workflows became 50% faster. Cross also said the platform transformed data management by bringing together information that had previously been spread across multiple systems.
The launch follows a period of significant activity for DeepIntent. Earlier this year, the company secured $637 million from Vitruvian Partners. Founded in 2016, DeepIntent was acquired by Propel Media in 2017 and later became the target of a buyout proposal from IQVIA in 2022, although that transaction was not completed after facing opposition from the Federal Trade Commission. Meanwhile, IQVIA has continued expanding its own AI portfolio, unveiling technology this week aimed at helping pharmaceutical marketers identify nurse practitioners and physician assistants who write prescriptions.
